The United Kingdom and the United States have announced a major commercial pact that will maintain zero tariffs on UK medicine exports being sold in the American market.
Key Provisions of the Pact
Under the terms of the agreement, the UK has pledged to increase funding on medicines through the NHS. This commitment guarantees that duties on these vital products will be held at zero for a timeframe of the next three years.
This deal follows previous statements to significantly raise duties on patented drug products, with figures floated reaching double the cost.
"This arrangement with the United Kingdom bolsters the global environment for innovative medicines and introduces much-needed fairness to American-British drug exports," a release noted.
Commercial Significance
Drugs are one of the Britain's most significant exports to the US, which is clearly the largest market for leading British pharmaceutical firms.
Export figures show that in the 12 months to the end of the third quarter, the UK exported drugs worth £11.1bn to the US. This amount accounted for 17.4% of all goods exports in that timeframe.
"This agreement protects employment, boosts capital expenditure and sets the stage for the UK to emerge as a global hub for life sciences," a minister stated.
Detailed UK Commitments
The pact involves several key commitments from the UK:
- Price Threshold Increase: The UK will increase the cost ceiling at which it considers new treatments to be too expensive by 25%.
- Higher Drug Budget: There is a goal to increase overall health service expenditure on treatments from 0.3% of GDP to 0.6% over the next decade.
- Rebate Cap: The amount drug companies must return to the NHS to prevent overspending will be capped at fifteen percent. In the past, rebates topped twenty percent.
Industry Background
This agreement comes amid a long-running row between the pharmaceutical industry and the UK government over medicine costs and approval rates.
This friction were exacerbated by assertions that US customers were paying a premium for the identical medicines than people in the other developed nations.
Over the last 18 months, several large drug company projects in the UK have been paused or abandoned, while major expansions have been announced toward American operations.
A senior figure acknowledged that the NHS needed to increase expenditure on treatments, noting that its budget allocation on drugs had decreased as a share of its overall budget over the past decade.
